CoChat
Sign Up
Cited by 331

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Diagnosis and Management of Pituitary Adenomas: A Review

Tritos, Nicholas A., Miller, Karen K.·2023·JAMA
DOI 10.1001/jama.2023.5444
Open this paper in CoChat — free account

Abstract

Importance: Pituitary adenomas are neoplasms of the pituitary adenohypophyseal cell lineage and include functioning tumors, characterized by the secretion of pituitary hormones, and nonfunctioning tumors. Clinically evident pituitary adenomas occur in approximately 1 in 1100 persons. Observations: Pituitary adenomas are classified as either macroadenomas (≥10 mm) (48% of tumors) or microadenomas (<10 mm). Macroadenomas may cause mass effect, such as visual field defects, headache, and/or hypopituitarism, which occur in about 18% to 78%, 17% to 75%, and 34% to 89% of patients, respectively. Thirty percent of pituitary adenomas are nonfunctioning adenomas, which do not produce hormones. Functioning tumors are those that produce an excess of normally produced hormones and include prolactinomas, somatotropinomas, corticotropinomas, and thyrotropinomas, which produce prolactin, growth hormone, corticotropin, and thyrotropin, respectively. Approximately 53% of pituitary adenomas are prolactinomas, which can cause hypogonadism, infertility, and/or galactorrhea. Twelve percent are somatotropinomas, which cause acromegaly in adults and gigantism in children, and 4% are corticotropinomas, which secrete corticotropin autonomously, resulting in hypercortisolemia and Cushing disease. All patients with pituitary tumors require endocrine evaluation for hormone hypersecretion. Patients with macroadenomas additionally require evaluation for hypopituitarism, and patients with tumors compressing the optic chiasm should be referred to an ophthalmologist for formal visual field testing. For those requiring treatment, first-line therapy is usually transsphenoidal pituitary surgery, except for prolactinomas, for which medical therapy, either bromocriptine or cabergoline, is usually first line. Conclusions and Relevance: Clinically manifest pituitary adenomas affect approximately 1 in 1100 people and can be complicated by syndromes of hormone excess as well as visual field defects and hypopituitarism from mass effect in larger tumors. First-line therapy for prolactinomas consists of bromocriptine or cabergoline, and transsphenoidal pituitary surgery is first-line therapy for other pituitary adenomas requiring treatment.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.2023.5444

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 64

  1. Molitch, 2017, Diagnosis and treatment of pituitary adenomas: a review., JAMA, 317, 516, 10.1001/jama.2016.19699 · DOI · Paper page
  2. Melmed, 2020, Pituitary-tumor endocrinopathies., N Engl J Med, 382, 937, 10.1056/NEJMra1810772 · DOI
  3. Hall, 1994, Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population., Ann Intern Med, 120, 817, 10.7326/0003-4819-120-10-199405150-00001 · DOI
  4. Molitch, 2014, Nonfunctioning pituitary tumors., Handb Clin Neurol, 124, 167, 10.1016/B978-0-444-59602-4.00012-5 · DOI
  5. Daly, 2006, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium., J Clin Endocrinol Metab, 91, 4769, 10.1210/jc.2006-1668 · DOI
  6. Fontana, 2009, Epidemiology of pituitary adenoma: results of the first Swiss study., Rev Med Suisse, 5, 2172
  7. Fernandez, 2010, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)., Clin Endocrinol (Oxf), 72, 377, 10.1111/cen.2010.72.issue-3 · DOI
  8. Gruppetta, 2013, Prevalence and incidence of pituitary adenomas: a population based study in Malta., Pituitary, 16, 545, 10.1007/s11102-012-0454-0 · DOI
  9. Agustsson, 2015, The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study., Eur J Endocrinol, 173, 655, 10.1530/EJE-15-0189 · DOI
  10. Al-Dahmani, 2016, Sellar masses: an epidemiological study., Can J Neurol Sci, 43, 291, 10.1017/cjn.2015.301 · DOI
  11. Day, 2016, Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a health management organization in Buenos Aires, Argentina., Arch Endocrinol Metab, 60, 554, 10.1590/2359-3997000000195 · DOI
  12. Limumpornpetch, 2022, The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality., J Clin Endocrinol Metab, 107, 2377, 10.1210/clinem/dgac265 · DOI
  13. Molitch, 2008, Nonfunctioning pituitary tumors and pituitary incidentalomas., Endocrinol Metab Clin North Am, 37, 151, 10.1016/j.ecl.2007.10.011 · DOI
  14. Klibanski, 2010, Clinical practice: prolactinomas., N Engl J Med, 362, 1219, 10.1056/NEJMcp0912025 · DOI
  15. Lacroix, 2015, Cushing’s syndrome., Lancet, 386, 913, 10.1016/S0140-6736(14)61375-1 · DOI · Paper page
  16. Amlashi, 2016, Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management., Endocrine, 52, 427, 10.1007/s12020-016-0863-3 · DOI
  17. De Herdt, 2021, Endocrine tumours: thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases., Eur J Endocrinol, 185, R65, 10.1530/EJE-21-0162 · DOI
  18. Melmed, 2022, Clinical biology of the pituitary adenoma., Endocr Rev, 43, 1003, 10.1210/endrev/bnac010 · DOI
  19. Klibanski, 1986, Increase in bone mass after treatment of hyperprolactinemic amenorrhea., N Engl J Med, 315, 542, 10.1056/NEJM198608283150903 · DOI
  20. Ben-Shlomo, 2008, Acromegaly., Endocrinol Metab Clin North Am, 37, 101, 10.1016/j.ecl.2007.10.002 · DOI
  21. Dal, 2018, Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature., J Clin Endocrinol Metab, 103, 2182, 10.1210/jc.2017-02457 · DOI
  22. Katznelson, 2014, Acromegaly: an Endocrine Society clinical practice guideline., J Clin Endocrinol Metab, 99, 3933, 10.1210/jc.2014-2700 · DOI
  23. Ribeiro-Oliveira, 2011, Limited utility of oral glucose tolerance test in biochemically active acromegaly., Eur J Endocrinol, 164, 17, 10.1530/EJE-10-0744 · DOI
  24. Dobri, 2019, Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?, Endocrine, 64, 139, 10.1007/s12020-018-1805-z · DOI
  25. Fleseriu, 2021, Consensus on diagnosis and management of Cushing’s disease: a guideline update., Lancet Diabetes Endocrinol, 9, 847, 10.1016/S2213-8587(21)00235-7 · DOI · Paper page
  26. Hong, 2015, Limited diagnostic utility of plasma adrenocorticotropic hormone for differentiation between adrenal Cushing syndrome and Cushing disease., Endocrinol Metab (Seoul), 30, 297, 10.3803/EnM.2015.30.3.297 · DOI
  27. Beck-Peccoz, 2013, 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors., Eur Thyroid J, 2, 76, 10.1159/000351007 · DOI
  28. MacFarlane, 2020, Advances in the imaging of pituitary tumors., Endocrinol Metab Clin North Am, 49, 357, 10.1016/j.ecl.2020.06.002 · DOI
  29. Araujo-Castro, 2022, Radiological Knosp, revised-Knosp, and Hardy-Wilson classifications for the prediction of surgical outcomes in the endoscopic endonasal surgery of pituitary adenomas: study of 228 cases., Front Oncol, 11, 10.3389/fonc.2021.807040 · DOI
  30. Karavitaki, 2006, Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? a study of 226 patients with histologically verified non-functioning pituitary macroadenoma., Clin Endocrinol (Oxf), 65, 524, 10.1111/cen.2006.65.issue-4 · DOI
  31. Ramshanker, 2017, Effects of prednisolone on serum and tissue fluid IGF-I receptor activation and post-receptor signaling in humans., J Clin Endocrinol Metab, 102, 4031, 10.1210/jc.2017-00696 · DOI
  32. Macchia, 2014, Clinical and genetic characteristics of a large monocentric series of patients affected by thyroid hormone (Th) resistance and suggestions for differential diagnosis in patients without mutation of Th receptor ß., Clin Endocrinol (Oxf), 81, 921, 10.1111/cen.12556 · DOI
  33. Roelfsema, 2012, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis., Pituitary, 15, 71, 10.1007/s11102-011-0347-7 · DOI
  34. Wright, 2021, Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis., World Neurosurg, 154, e349, 10.1016/j.wneu.2021.07.035 · DOI
  35. Starnoni, 2016, Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis., Acta Neurochir (Wien), 158, 2109, 10.1007/s00701-016-2903-4 · DOI
  36. Nunes, 2015, Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system., Pituitary, 18, 500, 10.1007/s11102-014-0602-9 · DOI
  37. Nieman, 2015, Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline., J Clin Endocrinol Metab, 100, 2807, 10.1210/jc.2015-1818 · DOI · Paper page
  38. Stroud, 2020, Outcomes of pituitary surgery for Cushing’s disease: a systematic review and meta-analysis., Pituitary, 23, 595, 10.1007/s11102-020-01066-8 · DOI
  39. Wang, 2012, Treatment of hyperprolactinemia: a systematic review and meta-analysis., Syst Rev, 1, 33, 10.1186/2046-4053-1-33 · DOI
  40. Giraldi, 2020, The role of dopamine agonists in pituitary adenomas., Endocrinol Metab Clin North Am, 49, 453, 10.1016/j.ecl.2020.05.006 · DOI
  41. Luger, 2021, ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy., Eur J Endocrinol, 185, G1, 10.1530/EJE-21-0462 · DOI
  42. Zamanipoor Najafabadi, 2020, Surgery as a viable alternative first-line treatment for prolactinoma patients: a systematic review and meta-analysis., J Clin Endocrinol Metab, 105, e32, 10.1210/clinem/dgz144 · DOI
  43. Carmichael, 2014, Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis., J Clin Endocrinol Metab, 99, 1825, 10.1210/jc.2013-3757 · DOI
  44. Giustina, 2012, Meta-analysis on the effects of octreotide on tumor mass in acromegaly., PLoS One, 7, 10.1371/journal.pone.0036411 · DOI
  45. Melmed, 2015, Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial., J Clin Endocrinol Metab, 100, 1699, 10.1210/jc.2014-4113 · DOI
  46. Colao, 2014, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study., J Clin Endocrinol Metab, 99, 791, 10.1210/jc.2013-2480 · DOI
  47. Sandret, 2011, Place of cabergoline in acromegaly: a meta-analysis., J Clin Endocrinol Metab, 96, 1327, 10.1210/jc.2010-2443 · DOI
  48. Fleseriu, 2021, More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY., Eur J Endocrinol, 185, 525, 10.1530/EJE-21-0239 · DOI
  49. Trainer, 2000, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant., N Engl J Med, 342, 1171, 10.1056/NEJM200004203421604 · DOI
  50. van der Lely, 2001, Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist., Lancet, 358, 1754, 10.1016/S0140-6736(01)06844-1 · DOI
  51. Broersen, 2018, Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis., Pituitary, 21, 631, 10.1007/s11102-018-0897-z · DOI
  52. Carroll, 2018, Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol., J Endocr Soc, 3, 1, 10.1210/js.2018-00269 · DOI
  53. Leonart, 2018, Medical treatments for acromegaly: a systematic review and network meta-analysis., Value Health, 21, 874, 10.1016/j.jval.2017.12.014 · DOI
  54. Fleseriu, 2021, A Pituitary Society update to acromegaly management guidelines., Pituitary, 24, 1, 10.1007/s11102-020-01091-7 · DOI
  55. Bonert, 2020, Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial., J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa444 · DOI
  56. Qiao, 2020, Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies., Endocr Pract, 26, 454, 10.4158/EP-2019-0528 · DOI
  57. Giustina, 2020, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update., J Clin Endocrinol Metab, 105, 10.1210/clinem/dgz096 · DOI
  58. Lacroix, 2018, Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial., Lancet Diabetes Endocrinol, 6, 17, 10.1016/S2213-8587(17)30326-1 · DOI
  59. Loeffler, 2011, Radiation therapy in the management of pituitary adenomas., J Clin Endocrinol Metab, 96, 1992, 10.1210/jc.2011-0251 · DOI
  60. Mathieu, 2021, Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations., J Neurosurg, 136, 801, 10.3171/2021.2.JNS204440 · DOI
  61. Fernández-Balsells, 2011, Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis., J Clin Endocrinol Metab, 96, 905, 10.1210/jc.2010-1054 · DOI
  62. Bolfi, 2018, Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis., Eur J Endocrinol, 179, 59, 10.1530/EJE-18-0255 · DOI
  63. Papakokkinou, 2020, Excess morbidity persists in patients with Cushing’s disease during long-term remission: a Swedish nationwide study., J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa291 · DOI
  64. Tritos, 2018, Prolactin and its role in human reproduction., 58

Cited by

Sorted by citations

See all 331

Metadata

Authors
Tritos, N. A., & Miller, K. K.
Affiliations
Neuroendocrine Unit, Massachusetts General Hospital, Boston
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2023-04-25
Volume
329
Issue
16
Pages
1386
ISSN
0098-7484
DOI
10.1001/jama.2023.5444
Cited by
331
References
14
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review